Proteasome Inhibitor News and Research

RSS
FDA ODAC votes in favor of Onyx’s Kyprolis

FDA ODAC votes in favor of Onyx’s Kyprolis

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

Three-drug regimen provides rapid, durable responses for multiple myeloma

Three-drug regimen provides rapid, durable responses for multiple myeloma

SLU investigator aims to reduce chemotherapy-induced peripheral neuropathy

SLU investigator aims to reduce chemotherapy-induced peripheral neuropathy

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Biochemists determine first crystal structure of an immunoproteasome

Biochemists determine first crystal structure of an immunoproteasome

MAL3-101 appears to have potent anti-tumor effects on multiple myeloma

MAL3-101 appears to have potent anti-tumor effects on multiple myeloma

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

Onyx announces data from three carfilzomib studies on RRMM

Onyx announces data from three carfilzomib studies on RRMM

SCRI to present findings of blood cancer trials at 53rd ASH annual meeting

SCRI to present findings of blood cancer trials at 53rd ASH annual meeting

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma

Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

John Theurer Cancer Center presents research findings at ASH meeting

John Theurer Cancer Center presents research findings at ASH meeting